SI-BONE (SIBN) Q3 2026 Earnings Call Transcript
SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.
How this was made
The 30-second read
Why it matters
The disclosed guidance and FDA clearance provide fresh material that could move the stock.
Market read
Earnings and product news are likely to drive short‑term price action.
What to watch
Potential competition from larger med‑tech firms could limit market share.
Background
SI‑BONE presented its Q3 2026 earnings call, highlighting volume growth, EBITDA expansion, and new product approvals.
Ticker impact
Q3 2026 earnings call disclosed double‑digit volume growth, 32% adjusted EBITDA increase and new FDA 510(k) clearance for Onyx.
likely upward pressure as investors price higher guidance and new product pipeline.
Guidance implies >20% Q4 revenue growth; FDA clearance and reimbursement changes are material catalysts.
Market effects
Spine‑fusion device sector may see broader valuation lift from SI‑BONE's product rollout.
U.S. healthcare investors could benefit from higher reimbursement rates.
Limited to U.S. med‑tech niche.
Counterpoint
If reimbursement reforms stall, growth may be slower than guidance suggests.
Key entities
- companySI‑BONE
U.S. med‑tech firm developing spine‑fusion devices.
